Phase 3, multicenter, long-term extension study of 104 weeks in patients with axial spondyloarthritis

Update Il y a 4 ans
Reference: EUCTR2016-002634-69

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate in patients having achieved a state of sustained remission whether the ixekizumab treatment group is superior to the placebo group in maintaining response during the randomized-withdrawal period


Inclusion criteria

  • Axial Spondyloarthritis